Quick answer
What is cagrilintide? Cagrilintide, also called cagri and, in early papers, AM833, is a synthetic long-acting analog of the hormone amylin. It carries aggregation-reducing substitutions, a disulfide ring and a fatty-diacid side chain that binds albumin. It acts at the calcitonin receptor and the RAMP-dependent amylin receptors, which are separate from the incretin receptors. The V8 product page lists a 10 mg lyophilized vial, ≥98% purity by HPLC and a molecular formula of C194H308N54O61, supplied for laboratory research use only.
This primer is for readers who have seen the name cagrilintide and want a clear starting point before reading the detailed literature. It answers the basic questions in the order they usually come up: what the compound is, what it is called, what is in the vial, which receptors it acts on, how it differs from compounds it is often listed beside, and what a laboratory actually does with it. Deeper treatments are linked at each step, including the full cagrilintide research guide. Cagrilintide is supplied for laboratory research use only; not for human consumption.
What cagrilintide is, in one paragraph
Cagrilintide is a synthetic peptide modeled on amylin, a 37-residue hormone made by pancreatic beta cells and released together with insulin. The native hormone is short-lived and prone to forming fibrils, so the analog was engineered with substitutions that reduce aggregation, a retained disulfide ring, and a fatty-diacid side chain that binds albumin and lengthens persistence in experimental systems. The design work was reported by Kruse and colleagues in the Journal of Medicinal Chemistry in 2021. In a laboratory it serves as a tool compound for studying amylin and calcitonin receptor signaling.
Names, codes and shorthand
One of the first sources of confusion is naming. The same molecule appears under several labels, and a literature search for one will miss papers that use another.
| Label | What it is | Where it appears |
|---|---|---|
| --- | --- | --- |
| Cagrilintide | The nonproprietary name of the compound | Papers, catalogs, this site |
| Cagri | Informal shorthand | Laboratory conversation, forums, search queries |
| AM833 | An early development code used in preclinical papers | Rodent and mechanism studies |
| Long-acting amylin analog | A descriptive phrase for the class | Reviews and abstracts |
| Amylin analog | A broader class that includes older compounds such as pramlintide | General discussion |
When reading a paper, check which label it uses before concluding that nothing has been published on a topic; some early work uses only the development code, and conference abstracts use it more often than the nonproprietary name. The older amylin analog pramlintide is a different molecule with a different profile, and cagrilintide versus pramlintide lays out the comparison.
What is in the vial
The facts below come from the V8 cagrilintide product page.
| Property | Value on the product page |
|---|---|
| --- | --- |
| Size | 10 mg |
| Purity | ≥98% by HPLC |
| Molecular formula | C194H308N54O61 |
| Supplied form | Lyophilized powder |
| Container | Sealed clear glass research vial |
| Storage | Refrigerate at 2–8 °C; −20 °C for long-term; protect from heat, moisture and light |
| Identity | Reported on the certificate of analysis, where published |
Lyophilized means freeze-dried: the peptide was frozen in solution and the water removed under vacuum, leaving a dry cake. It is the most stable state a peptide can be shipped in, and it is also the reason a vial must be dissolved in a suitable diluent before use. What is lyophilization explains the process. The certificate of analysis, when one has been published for the lot, reports purity and identity; the COA library is where to look, and how to read a COA explains each field.
Which receptors it acts on
Amylin acts through receptors that are built from two kinds of protein. The calcitonin receptor is a class B G-protein-coupled receptor. When it pairs with a receptor-activity-modifying protein, RAMP1, RAMP2 or RAMP3, the complex becomes a receptor for amylin, labelled AMY1, AMY2 and AMY3 respectively. This arrangement was worked out in the late 1990s (Christopoulos et al., 1999) and is reviewed by Hay and colleagues. Cagrilintide is described as an agonist at both the calcitonin receptor and the RAMP-containing amylin receptor complexes, which is why it is called a dual amylin and calcitonin receptor agonist in some papers.
That makes it a different kind of tool from the GLP-1, GIP and glucagon receptor agonists such as semaglutide, tirzepatide and retatrutide, whose targets are a separate family of receptors. The two systems are often studied together because both are involved in metabolic signaling, but the receptor biology is not shared. A short comparison of the targets is in GLP-1 receptor agonists in research.
What laboratories use it for
Three kinds of work account for most use.
Receptor pharmacology
Cell lines that express the calcitonin receptor with or without a RAMP partner are used to measure binding and cAMP signaling. Cagrilintide is run alongside native amylin and calcitonin to see how potency and selectivity differ.
Animal-model research
Rodent studies have characterized the compound's effects on food intake, body weight, and signaling in models of metabolic disease; the main findings are summarized in the cagrilintide rodent literature article and discussed in the related preclinical overview. These are experimental findings in animals and should not be read as statements about any outcome in people.
Combination and formulation work
Investigators combine it with GLP-1 pathway peptides in preclinical models to ask how amylin-axis and incretin-axis signals interact; background is in cagrilintide and semaglutide combination research. Analytical chemists use it as a case study for lipidated peptide stability, aggregation and adsorption.
What it is not
A few clarifications prevent common misunderstandings. It is not a GLP-1 receptor agonist and it does not act on incretin receptors. It is not the same molecule as human amylin, and its behavior in solution differs. It is not interchangeable with pramlintide. And it is not a product for any use outside the laboratory: the vial is a research reagent, not a drug, food or cosmetic.
Getting started: a first-use checklist
Before opening a vial, read the product page and the certificate of analysis if one is listed for the lot. Record the lot number and the date of receipt. Keep the sealed vial in the cold, protected from light. Decide the stock concentration the experiment needs, and work out the diluent volume with the formula concentration equals vial mass divided by volume; the reconstitution calculator does the arithmetic and prevents slips. Reconstitute slowly, because the lipid makes the solution foam, and log every step. Reconstitution calculator guide and how to reconstitute a lyophilized peptide are the generic references. For a stock that will be entered more than once, bacteriostatic water is the usual diluent; the page on bacteriostatic water explained discusses its properties and limits.
Reading the quality documents
A primer should also say what the paperwork means. The purity on the product page is an HPLC figure, the share of detected peak area belonging to the main peak. It is not net peptide content, and it does not by itself prove identity. Identity is shown by a mass measurement and, where available, a sequence confirmation, and the page states that these are reported on the certificate of analysis where published. For a molecule with a lipid chain and a ring, ask whether the document names the method, the lot and the date. Understanding HPLC purity and HPLC versus mass spectrometry explain why both techniques are useful and what each can miss.
Common first-week mistakes
- Shaking the vial to dissolve the cake, which creates foam and encourages self-association in this amphiphilic molecule.
- Adding a buffer that contains a reducing agent, which opens the disulfide ring.
- Using standard polypropylene tubes for very dilute solutions, which lets the peptide stick to the walls.
- Refreezing a thawed stock repeatedly instead of dividing it into single-use portions.
- Copying a concentration from a paper without converting between mass and molar units.
- Not recording the lot number, so a later discrepancy cannot be traced.
- Assuming the stock keeps its label concentration indefinitely, when adsorption and degradation can both lower it over time.
None of these mistakes is exotic; each follows directly from the lipidated, ring-containing structure described above, which is why a short checklist taped to the bench pays for itself.
Where to go next
Readers who want a broader view of the category can continue to what are research peptides, and those who want the neighboring compound stories can read cagrilintide versus tirzepatide or where to buy cagrilintide for a documentation-first look at supply. Anyone designing handling around a freshly received vial should also read storing research peptides.
Frequently asked questions
What does cagrilintide mean?
It is the nonproprietary name for a synthetic long-acting analog of amylin. Informally it is shortened to cagri, and early preclinical papers use the development code AM833.
Is cagrilintide the same as amylin?
No. It is modeled on amylin but carries engineered substitutions, a fatty-diacid side chain and a linker. These changes alter its aggregation, albumin binding and persistence compared with the native hormone.
Is cagrilintide a GLP-1 agonist?
No. It acts on amylin and calcitonin receptors, a different receptor family from the GLP-1, GIP and glucagon receptors. It is often studied alongside GLP-1 pathway compounds for comparison.
What form does V8 supply cagrilintide in?
According to the product page, a 10 mg lyophilized powder in a sealed clear glass research vial, stated as ≥98% pure by HPLC and stored at 2–8 °C, or −20 °C for long-term.
What is AM833?
It is a development code used for the compound in some early preclinical publications. Searching for it, as well as for the name cagrilintide, finds studies that the nonproprietary name alone would miss.
How is cagrilintide different from pramlintide?
Pramlintide is an older amylin analog without a lipid side chain, so it is cleared quickly and does not bind albumin. Cagrilintide's fatty-diacid side chain gives it albumin binding and longer persistence in experimental systems.
What are the main laboratory uses of cagrilintide?
Receptor binding and signaling assays at amylin and calcitonin receptors, animal-model metabolic research, combination studies with incretin-pathway peptides and stability or formulation analytics for lipidated peptides.
How is the concentration of a cagrilintide stock calculated?
Divide the vial mass by the volume of diluent added. Net peptide content may be lower than the nominal mass, so critical experiments should confirm the stock concentration by an independent method.
Is cagrilintide approved for any use outside research?
This site sells it only as a laboratory research reagent. It makes no claims about medical use, and the vial is not a drug, food or cosmetic.
Related reading: Cagrilintide Rodent Studies: What Papers Report, How to Evaluate a Cagrilintide Supplier for Lab Work, Cagrilintide Stability: Factors and Shelf-Life Studies.
References
- Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183-11194. doi:10.1021/acs.jmedchem.1c00565
- Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD, Poyner DR. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67(3):564-600. doi:10.1124/pr.115.010629
- Christopoulos G, Perry KJ, Morfis M, et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol. 1999;56(1):235-242. doi:10.1124/mol.56.1.235
- Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002;54(2):233-246. doi:10.1124/pr.54.2.233
- Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011;91(3):795-826. doi:10.1152/physrev.00042.2009
- Lutz TA. Control of energy homeostasis by amylin. Cell Mol Life Sci. 2012;69(12):1947-1965. doi:10.1007/s00018-011-0905-1
